We are live on ! Find out more
ASMB icon

Assembly Biosciences

98 hedge funds and large institutions have $204M invested in Assembly Biosciences in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,252% more call options, than puts

Call options by funds: $5.48M | Put options by funds: $126K

0.16% less ownership

Funds ownership: 6.88%6.72% (-0.16%)

8% less funds holding

Funds holding: 10698 (-8)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

29% less capital invested

Capital invested by funds: $286M → $204M (-$82.3M)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
98
Holders Change
-8
Holders Change %
-7.55%
% of All Funds
2.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
32
Reduced
37
Closed
19
Calls
$5.48M
Puts
$126K
Net Calls
+$5.36M
Net Calls Change
-$2.3M

ASMB Hedge Fund Activity: Q3 2019 in Review

98 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2019, worth a combined $204M — down 29% from $286M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ASMB and 11 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 32 added.

The largest buyer was Rock Springs Capital Management, adding an estimated $9.33M. The largest seller was OrbiMed, exiting entirely with an estimated $7.06M sold.

  • 98 institutional investors held Assembly Biosciences (ASMB) as of Q3 2019, down from 106 in Q2 2019.
  • Funds reported $204M of Assembly Biosciences stock for Q3 2019, down 29% quarter-over-quarter.
  • 11 funds opened new Assembly Biosciences positions in Q3 2019 and 19 closed out, a net change of -8 holders.
  • The largest Assembly Biosciences buyer in Q3 2019 was Rock Springs Capital Management, an estimated $9.33M added.
  • The largest Assembly Biosciences seller in Q3 2019 was OrbiMed, an estimated $7.06M sold.

Based on aggregated 13F filings for Q3 2019.